Pterostilbene is a dietary supplement, a berry-derived relative of the red-wine compound resveratrol, of interest for healthy aging. Human evidence is thin: the clearest signal is a modest blood-pressure drop at the higher tested dose, with weaker liver-health hints when paired with a vitamin B3 form. The most consistent risk signal is a rise in "bad" cholesterol. Claimed brain, cancer and lifespan benefits rest on laboratory and animal research. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | <100 mg/dL (<70 mg/dL at high cardiovascular risk) | Main known risk |
| ApoB | <80 mg/dL (≤60 mg/dL at high risk) | Particle-level lipid risk |
| Blood pressure | <120/80 mmHg | Benefit and low-pressure risk |
| ALT | <25 U/L | Liver signal |
| GGT | <25 U/L | Liver signal |
| Fasting glucose | 75–90 mg/dL | Glucose interplay |
| HbA1c | <5.4% | Longer-term glucose |
| INR (warfarin users only) | Prescriber's target, usually 2.0–3.0 | CYP2C9 interaction |
| hs-CRP | <1.0 mg/L | Inflammation claims |
| Whole-blood NAD+ | No established target; track change from own baseline | Nicotinamide riboside + pterostilbene response |
Cadence: Baseline before starting; INR at 1 and 2 weeks (warfarin users only); home blood pressure at 2, 4 and 8 weeks; lipids and liver enzymes at 6–8 weeks, then every 6–12 months while use continues